Lysogene Appoints Dr. Kimberley S. Gannon as Chief Scientific Officer

Dr. Gannon brings her broad-based expertise in Neurosciences to further advance Lysogene’s gene therapies for neurodegenerative conditions PARIS–(BUSINESS WIRE)–Lysogene, a biotechnology company specializing in gene therapy technology applied to central nervous system diseases, has appointed Kimberley S. Gannon, PhD, as its Chief Scientific Officer. Dr. Gannon brings over 15 years of industry experience in CNS research and development at major pharmaceutical firms and early stage biotech companies to strengthen and accelerate Lysogene’s development programs in Mucopolysaccharidosis Type A (also known as Sanfilippo A) and GM1 Gangliosidosis. Dr. Gannon will be based in Lysogene’s U.S. office in Cambridge, Mass., and report directly to CEO Karen Aiach. “We are eager to welcome Dr. Gannon aboard during this exciting period of growth for Lysogene,” said CEO Karen Aiach. “Dr. Gannon’s scientific background and…


Link to Full Article: Lysogene Appoints Dr. Kimberley S. Gannon as Chief Scientific Officer